It is within this subset of melanoma cells defined by high PGC1α levels and elevated oxidative phosphorylation where we find that chronic-adaptation to BRAF-inhibitor treatment leads to emergence of an alternative epigenetic-state that involves silencing of PGC1α-function and upregulation of integrin receptors. The gene discussed is PPARGC1A; the disease is melanoma.